Meeting
2016 Genitourinary Cancers Symposium
Identification of a predictive factor of metastatic castration-resistant prostate cancer patients’ response to alternative antiandrogen therapy with flutamide.
Authors
Masato Yasui
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
Masato Yasui , Shuko Yoneyama , Koichi Uemura , Takashi Kawahara , Yusuke Hattori , Jun-ichi Teranishi , Jun-ichi Ohta , Yumiko Yokomizo , Masahiro Yao , Masataka Taguri , Hiroji Uemura , Yasuhide Miyoshi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 321)
DOI
10.1200/jco.2016.34.2_suppl.321
Abstract #
321
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.
First Author: Goutam Chakraborty
Poster
2018 ASCO Annual Meeting
CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.
First Author: Gang Chen
Poster
2024 ASCO Genitourinary Cancers Symposium
Nucleosome profiling at AR binding sites (ARBS) to provide a prognostic tool for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Chao Dai
Poster
2024 ASCO Genitourinary Cancers Symposium
Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.
First Author: Yushi Naito